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Abstract
Introduction The objectives of this study were to systematically
identify and summarize quality indicators of tight glycaemic
control in critically ill patients, and to inspect the applicability of
their definitions.
Methods We searched in MEDLINE® for all studies evaluating
a tight glycaemic control protocol and/or quality of glucose
control that reported original data from a clinical trial or
observational study on critically ill adult patients.
Results Forty-nine studies met the inclusion criteria; 30 different
indicators were extracted and categorized into four
nonorthogonal categories: blood glucose zones (for example,
'hypoglycaemia'); blood glucose levels (for example, 'mean
blood glucose level'); time intervals (for example, 'time to
occurrence of an event'); and protocol characteristics (for
example, 'blood glucose sampling frequency'). Hypoglycaemia-
related indicators were used in 43 out of 49 studies, acting as a
proxy for safety, but they employed many different definitions.
Blood glucose level summaries were used in 41 out of 49
studies, reported as means and/or medians during the study
period or at a certain time point (for example, the morning blood
glucose level or blood glucose level upon starting insulin
therapy). Time spent in the predefined blood glucose level
range, time needed to reach the defined blood glucose level
target, hyperglycaemia-related indicators and protocol-related
indicators were other frequently used indicators. Most indicators
differ in their definitions even when they are meant to measure
the same underlying concept. More importantly, many definitions
are not precise, prohibiting their applicability and hence the
reproducibility and comparability of research results.
Conclusions An unambiguous indicator reference subset is
necessary. The result of this systematic review can be used as
a starting point from which to develop a standard list of well
defined indicators that are associated with clinical outcomes or
that concur with clinicians' subjective views on the quality of the
regulatory process.
Introduction
Hyperglycaemia is frequently encountered in critically ill
patients [1,2]. Even critically ill patients without diabetes
develop hyperglycaemia. Until recently it was common prac-
tice to treat only marked hyperglycaemia in these patients,
because hyperglycaemia was considered to be an adaptive
response to critical illness [3]. Blood glucose control aiming to
achieve normoglycaemia (blood glucose levels of 80 to 110
mg/dl), frequently referred to as 'tight glycaemic control'
(TGC), decreases mortality and morbidity in critically ill
patients [4,5]. It is the lowered blood glucose level (BGL)
rather than the insulin dose that is related to reduced mortality
and morbidity [6]. Attempts at achieving TGC, however, are
not perfect and carry a risk for hypoglycaemia [4,5].
Several observational studies have reported on the quality of
the glucose control process itself. The results and conclusions
of these studies are contradictory [7]. Some show that the pro-
tocol prescribing the control process improves blood glucose
control whereas others do not. Apart from differences in case-
mix and in the associated therapy (for example, steroid ther-
apy), two important issues hamper comparability between
studies. The first impediment is the existing variability in the
intervention's evaluation. The following interpretations, based
BGL: blood glucose level; TGC: tight glycaemic control.Critical Care    Vol 12 No 6    Eslami et al.
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on intention and on process, are both possible: the patient is
intended to be treated according to a TGC protocol (for exam-
ple, when a specific intensive care unit is designated an inter-
vention group), independent of actual adherence to the
glucose control protocol; or the characterization of the
patient's blood glucose regulation is evaluated according to
the actual intensity of blood glucose control. The latter inter-
pretation requires agreement on the level of adherence to the
TGC protocol in terms of timing of glucose measurements and
insulin provision to qualify a patient as being on TGC. The sec-
ond impediment concerns the variability in outcome measures;
studies may not use a standard list of well defined indicators
for evaluating the quality of glucose control. Work presented
in this paper concerns this second impediment.
The objective of the present systematic review is to identify
and summarize quality indicators for glucose control in pub-
lished studies of TGC in critically ill patients. It also assesses
the applicability of definitions of quality indicators and organ-
izes the indicators into categories. This review may form a
basis for future developments of a standard list of well defined
indicators that may correlate with clinical outcomes or that
reflect clinicians' intuition regarding the quality of a given reg-
ulatory process.
Materials and methods
We searched for relevant English language articles based on
keywords in title, abstract and MeSH terms, using Ovid
MEDLINE®  and Ovid MEDLINE®  In-Process (1950 to 31
December 2007). The final literature search was performed on
31 December 2007.
The following search strategy was used to identify the relevant
articles. In the first stage we searched for 'glucose' and 'insu-
lin'. In the second stage we limited the search using 'critical ill-
ness', 'critical care' or 'intensive care'. The results of these two
stages were combined using the Boolean operator 'and'.
Searching was supplemented by scanning the bibliographies
of the identified articles.
Two reviewers independently examined all titles and abstracts.
Discrepancies between the two reviewers were resolved by
consensus involving a third reviewer. Articles were selected if
they reported original data from a clinical trial or observational
study conducted in critically ill adult patients, and only if one of
their main objectives concerned the evaluation of quality of
TGC, with or without implementing an explicitly specified pro-
tocol. A study was defined as evaluating a TGC protocol if the
(implicit or explicit) protocol implied an upper target range.
Adherence to the protocol did not influence whether the study
was included. Opinion papers, surveys and letters were
excluded. Studies employing glucose-insulin-potassium proto-
cols were excluded because they are not originally designed
to achieve TGC.
From the selected papers, the same two reviewers extracted
data on TGC quality indicators (their definition and applicabil-
ity). A quality indicator was defined as a measurable quantity
of the TGC process that may, alone or in combination with
other quantities, indicate some aspect of its quality. This
includes, for example, mean (or median) BGLs as well as inter-
pretations thereof in terms of counts of hyperglycaemic
events. Discrepancies between the two reviewers were again
resolved by consensus after involving the same third reviewer.
We then attempted to categorize the quality indicators into
coherent categories that capture their essence.
Results
Searching the online databases yielded 486 articles. Initial
screening of titles and abstracts resulted in 50 articles eligible
for further full-text review. One additional article was identified
by reviewing bibliographies, for a total of 51 articles. Based on
the full-text review, two studies were excluded because they
turned out not to address original data, leaving 49 articles for
detailed analysis. Only five out of 49 studies reported on a tar-
get upper limit above 150 mg/dl.
All quality indicators of the 49 studies are summarized in
Tables 1 and 2.
Most papers evaluated multiple quality indicators. The median
number of quality indicators was five (range 2 to 10).
By inspecting the quality indicators, we arrived at four indicator
categories based on the following: zones (adverse-zone
[hypoglycaemia and hyperglycaemia] and in-range zone);
BGLs (for example, mean morning BGL); time intervals (for
example, time elapsed until an event occurs or time spent in
some state); and protocol characteristics (for instance, blood
sampling frequency).
The categories are not mutually exclusive. For example, the
amount of time during which a patient is regarded to be in a
hyperglycaemic state is related to an adverse-zone as well as
to time. Below, we list indicators, in decreasing order of
reported frequency, and describe our findings about them.
Hypoglycaemia (adverse-zone and time categories)
Almost all studies reported at least one hypoglycaemia-related
indicator (43/49 studies). Hypoglycaemia-related indicators
address TGC safety. Because of its central position among
the TGC quality indicators reported, hypoglycaemia is
reported in Table 1 as an overall class of indicators.
Table 3 summarizes the concrete indicators used in this class
along with their definitions.
In total, 15 different thresholds of BGL were used to define a
hypoglycaemic event, varying from <40 mg/dl to <72 mg/dl.
These included four different thresholds to define mild andAvailable online http://ccforum.com/content/12/6/R139
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Table 1
List of applied quality indicators
Indicator Description References
Hypoglycaemiaa Represented in different ways. In most studies it is represented as 
the number or percentage of measurements below a certain BGL 
value and/or number or percentage of patients who experienced at 
least one measurement below a predefined BGL value
43 articles [8-13,15-35,42-57]
BGLs over time Represented as mean and/or median BGL values. Each BGL 
measurement or each patient was regarded the unit of observation. 
In one study, it was calculated as area under the glucose/time 
curve divided by total time per admission [10]. Mean or median 
BGL was also calculated:
￿ at the end of IIT [52];
￿ after the target range was achieved [9,33,49,54];
￿ after stopping IIT [45,55];
￿ for patients who had admission BGL above a threshold [10];
￿ during IIT [27] or during the last 5 hours of IIT [57];
￿ after 24 hours [15]; or
￿ 24 hours before, within and after IIT [39] or 48 hours after IIT [11]
37 articles [8-12,15,17,18,20-
22,24,26,27,29,30,32-36,39,42-47,49-
52,54-58]
Measurements in predefined 
BGL ranges
Represented as the number or percentage of measurements in a 
predefined BGL range:
￿ during the study;
￿ after the target is achieved [27,49,55,56]; or
￿ at the start of IIT [21]
Each BGL measurement, and in one study each patient [11], was 
considered the unit of observation
31 articles [9,11,12,17-21,25-28,30-
33,35,36,42-45,47,49-51,55-57,59,60]
Time to capture defined BGL 
target
Represented as:
￿ mean and median of time; or
￿ by Kaplan-Meier curve, as in [17,20,23,25,49]
In one study two successive BGL measurements in the target 
range were required before calculating time [20]
25 articles [8,9,11,15-
17,20,21,23,25,27,29,30,32-
34,43,45,46,49,52,53,55,56,59]
Frequency of measurements 
during the study
Represented as:
￿ mean or median per patient [11,16,17,23-28];
￿ mean or median per patient treatment day or days 
[12,15,21,22,26,27,29-31];
￿ sampling interval (time) [13,31-36];
￿ median frequency per patient-hour [23];
￿ percentage of patients with more than one measurement in 
predefined time interval (every 2 hours, and so on) [31];
￿ frequency overall per day [12,21]; or
￿ percentage of time in which at least one measurement per 2 
hours was taken [32].
23 articles [11-13,15-17,20-36]
BGL at starting IIT Represented as mean and median BGL 14 articles 
[9,11,13,16,21,27,29,33,46,52,54-56,59]
Protocol compliance Compare measurement times suggested by protocol with actual 
times of measurements and/or pump speed during IIT and/or at the 
time of hypoglycaemic events [9,21]. In one studya time-motion 
method was used to measure discrepancy in timing of BGL 
measurements between protocol and actual [28]
13 articles [9,11,13,14,16,21,28-
31,33,46,57]
Time in predefined range Represented as:
￿ mean of percentage of time per patient [12,32,58];
￿ median of fraction of time per patient [13,15,21,34];
￿ median of fraction of time per day [29];
￿ percentage of time for all patients [14,17,21,25]; or
￿ percentage of time 24 hours before, within and after trial [39]
12 articles [12-15,17,21,25,29,32,34,39,58]
Hyperglycaemic events Represented as:
￿ percentage of time >180b, >250 (severe hyperglycaemia) [16], 
or between 151 and 200 and >200 (severe hyperglycaemia) [21];
￿ percentage of patients with at least one measurement per day ≥ 
250 and ≥ 200) [22];
￿ percentage of measurements above 150 [11] or 180 [17-20]; or
￿ percentage of measurements and patients with at least one BGL 
above the 180 level for more than 2 hours [13]
9 articles [11,13,16-22]Critical Care    Vol 12 No 6    Eslami et al.
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moderate hypoglycaemia, and three different levels for defin-
ing severe or marked hypoglycaemia. Although a BGL <40
mg/dl was reported in eight studies as a hypoglycaemic event,
10 other studies considered this to be severe hypoglycaemia.
One study reported severe hypoglycaemia only when a low
BGL was accompanied by clinical symptoms such as sweat-
ing and decreased level of consciousness [8].
In some studies the number and/or percentage of BGL meas-
urements below a given threshold and/or the number and per-
centage of patients with at least one measurement below this
threshold were used as safety-related quality indicators. One
article considered all measurements below the selected
hypoglycaemic threshold value over a period of at least 1 hour
to represent a single hypoglycaemic event; hence only when
the BGL increased to within the normal range and then
dropped below the hypoglycaemic threshold in a subsequent
hour was it counted as a second hypoglycaemic event.
In other studies, the definition of hypoglycaemia was not clear,
and it appeared that any measurement below the threshold
was considered a hypoglycaemic event. Seven studies
reported the number and/or percentage of dextrose injections
when BGL was under a threshold value (using five different
thresholds from 45 to 65 mg/dl) as quality indicators. Seven
other indicators in this category were reported in at least one
out of nine studies. Except for 'time from starting TGC till first
hypoglycaemia', the other six indicators referred to the dura-
tion of hypoglycaemia or speed and quality of recovery after a
hypoglycaemic event.
BGL summaries over time (BGL category)
BGL summaries were used in 41 out of 49 studies. BGL sum-
maries correspond to the efficiency of TGC. This indicator was
calculated in different ways and was represented as mean
and/or median. In some studies the BGL itself was the unit of
observation. In other studies the mean BGL per patient or per
time unit (for example, 1 hour) was the unit of observation. One
Morning BGLs Represent as:
￿ mean BGL around 06:00 hours [43], between 06:00 and 12:00 
hours [50], or between 06:00 and 09:00 hours [19];
￿ mean lowest BGL between 06:00 and 09:00 [43];
￿ median between 06:00 and 08:00 hours [24] or between 03:00 
and 06:00 hours [27]; or
￿ mean of BGL, but morning time was not mentioned [20]
6 articles [19,20,24,27,43,50]
Hyperglycaemic index Represented as median area between glucose-time curve and 
upper normal range divided by time per patient during the trial 
[15,24], in first 24 hours [23,25] or in first 48 hours [17]. Upper 
normal range was 207 [23], 117 [15], 108 [24], 120 [17], and 
150 [25]. It was calculated with the same definition but without 
labeling as hypoglycaemic index [23,25]
5 articles [15,17,23-25]
Time until starting or 
adjusting IIT
Represented as mean or median of time until starting and/or 
adjusting IIT [9,10,27,28], or proportion of patients per time until 
starting IIT [12]. In one study a time-motion method was used [28]
5 articles [9,10,12,27,28]
Minimum and maximum 
recorded BGL
Represented as:
￿ minimum and maximum recorded BGL over all patients [35,47]; 
or
￿ median of minimum and maximum recorded BGL per patients 
[24] or per patient-day [29]
4 articles [24,29,35,47]
Number of patients with at 
least one BGL in predefined 
range
Represented as number and percentage per month [31] or at 
defined time interval after starting TGC [11] or during the study 
periods [60]
3 articles [11,31,60]
BGL change over time Represented as:
￿ speed of BGL change per hour [54]; or
￿ BGL change in first 24 hours [15]
2 articles [15,54]
Number of patients who 
achieved or did not achieve 
target or predefined range
Represented as number and percentage 2 articles [17,27]
Number of positive culture Represented as median (per patient) or rate (per year per patient). 2 article [31,59]
Target acquisition error Represented as absolute value and percentage of difference 
between the target BGL and achieved BGL
2 articles [32,48]
aHypoglycaemia is a concept in this table and related quality indicators are described in table 3. bUnit of all BGL thresholds is mg/dl. BGL, blood 
glucose level; IIT, intensive insulin therapy; TGC, tight glycaemic control.
Table 1 (Continued)
List of applied quality indicatorsAvailable online http://ccforum.com/content/12/6/R139
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study reported the mean and median of all BGLs as well as the
mean and median of BGL during each intensive insulin therapy
run [9]. 'Mean BGL' was also calculated as the area under the
glucose/time curve divided by the total time per admission
[10]. As long as there is no continuous measurement of BGLs
over time (provided at any time point), this measure reflects
mean BGL when BGL indeed behaves according to the
assumptions underlying the interpolation of consequent BGL
measurements.
BGLs are usually summarized as their mean at various points
in time or in time intervals, and they are presented in graphs
that show mean BGL versus time. Some studies used quality
indicators that refer to the mean or median BGL measured at
the end of TGC, before and after achieving the target range,
or after stopping TGC. Summary of morning BGL was
reported in six studies. The time used to define morning BGL
varied among the studies. BGL at starting TGC (reported in
14 out of 49 studies) was another frequently used indicator in
this group.
Measurements and time in predefined BGL ranges (in-
range zone and time categories)
Thirty-eight studies out of 49 examining the number of meas-
urements and/or the time during which BGL was within a pre-
defined range were reported. These indicators are intended to
address TGC efficiency. In 31 out of 49 of these studies, the
percentage of measurements within the predefined range was
considered a proxy for the proportion of time in each prede-
fined BGL range. In 12 out of 49 studies, the percentages of
time during which BGL was within the predefined range were
calculated, in most of them under the assumption that BGL
was linear over time. As shown in Figure 1, under this assump-
tion a straight line is drawn between each two consecutive
BGL measurements, and the time to the intersection between
the line and a threshold value defining the range was taken as
the time spent within the predefined BGL range. Five studies
used both the number/percentage of measurements within the
predefined range as well as the time during which BGL was
within the predefined range. The unit of observation differed
also among these studies. Only in one study was the percent-
age of measurements within the predefined range calculated
Table 2
List of applied quality indicators
Indicator Description References
Adequate daily blood glucose control Represented as median hours spent each day within the target range 
per patient
1 article [21]
Correlation between within-run mean BGL and within-
run mean coefficient of variance for hourly insulin rate
To illustrate whether hyperglycaemia after attaining target is 
correlated with variability in infusion rate
1 article [9]
Correlation between within-run mean BGL and within-
run mean hourly insulin rate
To illustrate whether the protocol performed equally well independent 
of insulin resistance
1 article [9]
Distribution of the individual patient BGL mean in a 
predefined time interval
Represented in box plot 1 article [11]
Number of patients with well and poor BGL control Represented as percentage of patients and defined as:
￿ well controlled patient: <130a BGL for more than half of the 
measured time; or
￿ poor controlled patient: <130 BGL for less than or equal to half of 
the measured time.
1 article [31]
Odds ratio of achieving certain BGL Per additional Intensive Care day and some drugs 1 article [50]
Number of patients having defined mean BGL Represented as percentage of patients with mean BGL ≥ 200 for 
each day after surgery
1 article [22]
Probability density function for BGL measurements Represented as a curve for comparison with other protocols 1 article [35]
Proportion of patient-day with mean BGL<200 and ≥ 
200 and IIT at least in part of the day
1 article [22]
Number of report on necessary departure from protocol, 
clinical intervention or adverse events
1 article [35]
Time from admission to first BGL Represented as mean of time [15] 1 articles [15]
Variability after achieving target Represented as within-run mean (IIT episode) ± standard deviation 
and mean of within-run coefficient variance ± standard deviation (%)
1 article [9]
aUnit of all BGL thresholds is mg/dl. BGL, blood glucose level; IIT, intensive insulin therapy.Critical Care    Vol 12 No 6    Eslami et al.
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Table 3
Hypoglycaemia quality indicator subgroups
Indicators Description Reference
Hypoglycaemic events Reported thresholdsa for defining a BGL as hypoglycaemic 
event:
￿ <40 [8,10,17-19,30,35,43];
￿ ≤ 40 [26];
￿ <45 [44,54];
￿ <50 [31,49,50];
￿ <54 [34];
￿ <57 [32];
￿ <60 [8,11,45,52,55];
￿ ≤ 60 [16,21];
￿ <63 [23];
￿ <65 [25];
￿ <70 [9,17,22,27,28,57];
￿ <72 [20]; or
￿ threshold was not reported [48]
Represented as:
￿ percentage and number of measurements and/or patients 
with hypoglycaemic event during the trial, or normalized for 
duration of therapy [16];
￿ mean or median of events per patient-day [57];
￿ mean of events per patient [27];
￿ patients with at least one event per day [22]; or
￿ in three studies, hypoglycaemic events did not occur and 
therefore were not reported [32,48,54]
31 articles [8-11,16-23,25-28,30-
32,34,35,43-45,48-50,52,54,55,57]
Severe or marked hypoglycaemic 
events
Reported threshold for defining a BGL as severe 
hypoglycaemic event:
￿ <40 [15,20,25,29,33,42,46,47,51,56];
￿ ≤ 40 [12,13,16];
￿ <48 [24]; or
￿ in one study clinical finding defined as severe 
hypoglycaemia [8]
Represented as:
￿ percentage and number of measurements and/or patients 
with severe hypoglycaemic event;
￿ mean or median of events per patient-day [29];
￿ In two studies severe hypoglycaemic events did not occur 
and therefore not reported [47,56]
15 articles 
[8,12,13,15,16,20,24,25,29,33,42,46,47,51
,56]
Need for dextrose injection Reported threshold for dextrose injection:
￿ <45 [29];
￿ <54 [44];
￿ <60 [53];
￿ <63 [23];
￿ <65 [25]; or
￿ threshold was not reported [21,56]
Represented as:
￿ percentage and number of patient with dextrose injection 
[21,23,29,44,53,56]; or
￿ percentage and number of dextrose injections [25]
7 articles [21,23,25,29,44,53,56]
Mild or moderate hypoglycaemic 
events
Reported threshold for defining an BGL as severe 
hypoglycaemic event:
￿ 40–59 [42];
￿ <60 [46];
￿ 40–60 [51];
￿ <63 [15]
Represented as percentage and number of measurements 
and/or patients with a moderate hypoglycaemic event
4 articles [15,42,46,51]
Hypoglycaemia duration Represented cumulatively [29], as median [24] and per 
patient [21]
3 articles [21,24,29]
Time until next in predefined range 
after hypoglycaemia
Represent as mean [8,49] or median [31] time 3 articles [8,31,49]
Duration of stopping IIT because of 
hypoglycaemia
Represented as median of percentage of time per patient 2 articles [29,33]
Next BGL after hypoglycaemia Represented as mean BGL 2 articles [8,49]Available online http://ccforum.com/content/12/6/R139
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per patient, and the mean percentage per patient was
reported [11].
Time to capture the defined BGL target (time category)
The time needed to capture the defined BGL target was
reported in 25 out of 49 studies and was represented as mean
or median.
Similar to the time-related indicators in the predefined BGL
range subcategory, in most of these studies it was unclear
how this indicator was calculated. Linearity of BGL over time
was explicitly mentioned in some studies [12-15] and
appeared to have been assumed in other studies. It is possible
that some of the studies might have used the time needed to
capture the actual first BGL measurement within the target
range, instead of the interpolated value shown in Figure 1.
Hyperglycaemic indicators (adverse zone category)
Although the reduction in duration of a hyperglycaemic period
forms a major goal of TGC, only 13 out of 49 studies explicitly
mentioned how a hyperglycaemic event or indicator were
defined. The threshold for considering a BGL measurement to
be hyperglycaemic varied among studies from >150 to >250
mg/dl. Four different thresholds for hyperglycaemia and two
thresholds for severe hyperglycaemia were reported. Six stud-
ies considered a BGL >180 mg/dl to be hyperglycaemic.
Among the definitions, hyperglycaemia was identified as the
percentage of time or of measurements above the threshold by
seven studies [11,16-21], by one study [22] as the percent-
age of patients with at least one measurement above the
threshold per day, and by one study [13] as a BGL above the
threshold for at least 2 hours.
The hyperglycaemic index of BGL was defined by determining
the area under the curve of BGL over time that is above the
hyperglycaemic threshold divided by time per patient
[15,17,23-25]. The thresholds varied between these studies
(from 108 to 207 mg/dl).
Sampling of BGL during the study, BGL at starting TGC 
and adherence to protocol (protocol category)
Sampling of BGL during the study was represented as mean
or median of number of measurements per patient
[11,16,17,23-28], per patient treatment day
[12,15,21,22,26,29,30] or over 2 days [31], sampling interval
[13,31-36], frequency per patient hour [23], percentage of
patients with more than one measurement in a predefined time
interval (2 hours) [31], or overall per day [12,21], and as the
percentage of time during which at least one measurement per
2 hours was taken [32].
Frequent BGL measurement is a key element in TGC, in order
to steer the process in a timely manner. However, greater sam-
pling frequency increases nursing and laboratory utilization
[30]. In some studies [14,18,19] the total number of BGL
measurements was reported.
Adherence to protocol (reported in 12/49 studies) is another
frequently used indicator. Evaluation of adherence to protocol
mainly focused on the difference between the protocol-recom-
mended time of the next BGL test and the actual time of
testing.
The remaining indicators (19/30) were mentioned in fewer
than six studies, and 12 of them in only one study.
Time until reaction to 
hypoglycaemic event
Represented as maximum time till hypoglycaemia 
recognition [8] or mean time till IIT adjustment after 
hypoglycaemic event [28]
2 articles [8,28]
Time from starting IIT until first 
hypoglycaemia
Represented as mean time 1 article [19]
Time till next BGL after 
hypoglycaemia
Represented as mean time 1 article [49]
aUnit of all BGL thresholds is mg/dl. BGL, blood glucose level; IIT, intensive insulin therapy.
Table 3 (Continued)
Hypoglycaemia quality indicator subgroups
Figure 1
BGL measurements against time BGL measurements against time. Presented is a graph of hypothetical 
BGL measurements against time, showing hyperglycaemic and 
hypoglycaemic events, time to capture first (interpolated or measured) 
BGL in defined range, hyperglycaemic index and mean BGL.Critical Care    Vol 12 No 6    Eslami et al.
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On the whole, the included studies did not comment on why a
specific group of indicators was selected, and – after further
inspection – we could not find an association between indica-
tor selection and patient population, disease or specification
of the designed protocols.
Discussion
We have identified, listed and categorized TGC quality indica-
tors, as used in 49 studies. In our search for studies pertaining
to TGC, we allowed any synonym, without limiting the search
a priori. A limitation of our search is that we addressed only
studies in which evaluation and quality measurement formed a
main objective; we might therefore have missed some studies
with a limited evaluation and quality measurement focus. In
addition, frequency was used as the ordering principle for pre-
senting and describing indicators. Although this approach pro-
vides a good overview of the popular indicators used, it may
overlook less frequent but useful indicators. Finally, although
indicator categories are useful in terms of managing and
understanding indicators, their induction is subjective. One
may for example also consider the complexity of calculation of
indicators (for instance, calculating mean BGL is simpler and
faster than time-weighted mean BGL).
To our knowledge this is the first review dedicated exclusively
to quality indicators for TGC in critically ill patients. Existing
reviews on TGC have focused on its effects [7,37]; evidence
of its utility and its advantages were reported, and ways to
implement TGC protocols successfully discussed.
Indicators and indicator groups have merits and limitations.
Measures of mean BGL may mask measurements within
adverse zones (for instance, two high BGLs may 'compensate'
for one or more BGLs that are too low). Looking at hypogly-
caemia and hyperglycaemic events separately would solve this
problem, but this requires a way to combine both indicators
into one quality indicator of blood glucose management. The
Glycaemic Penalty Index, proposed very recently [38], is an
attempt to address each zone and combine the two results.
Indicators that neglect measurement timing, including the Gly-
caemic Penalty Index, may be sensitive to sampling. For exam-
ple, the mean BGL of two determinations yielding the same
BGL value taken at t1 and t2 or at t1 and t3, where say t3 > t2,
will provide the same result, although the BGL – behaving as
a function of time – may differ markedly. The hyperglycaemia
index, which measures the area under the BGL over the time
during which it was above a threshold, can mitigate this prob-
lem. The use of BGL measurement as the independent unit of
observation neglects the within-patient correlation in BGLs.
On the other hand, when providing summaries at the patient
level, some information is lost. Finally, a statistical point worth
noting is that most BGL distributions are log-normal rather
than normal [39], and hence nonparametric measures such as
the median and interquartile range are likely to be more appro-
priate for summarizing the data and inference [40].
Because hypoglycaemia is the main potential risk from imple-
mentation of a TGC protocol, almost all studies reported at
least one indicator related to hypoglycaemia. The number of
hypoglycaemic events before and after TGC implementation
and/or the management of these events form the main TGC
safety indicators. However, we found several definitions and
ambiguous terminology for defining a blood glucose measure-
ment (or a set of measurements) a hypoglycaemic event.
Hypoglycaemic events were usually represented as the per-
centage or number of measurements below a defined level.
Based on most glucose management protocols, the next BGL
measurement after a hypoglycaemic event should be taken
within 15 to 30 minutes. Only one study clearly stated that all
measurements below the hypoglycaemia threshold over 1
hour after the first hypoglycaemic measurement were consid-
ered part of a single hypoglycaemic event or episode. In other
studies it was not clear how these hypoglycaemic measure-
ments where dealt with within a short interval, and hence
whether they were regarded a single or as multiple events.
Some studies also reported the number of dextrose injections
to address this problem, where each injection corresponds to
one hypoglycaemic event regardless of the number of meas-
urements within the short interval. Even in these studies, the
criteria and the BGL threshold for dextrose injection were
different.
Indicators such as the percentage or number of BGL measure-
ments and the time during which BGL was within predefined
ranges were frequently used to represent the time duration in
each predefined BGL range. However, the predefined ranges
were different in the various studies, once again hampering
comparability among them. Summary measures themselves,
like mean and median of BGLs, were calculated with different
units of analysis. Studies reporting the percentage of meas-
urements tended to base calculations on all BGL measure-
ments, regardless of the number of measurements of per
patient.
In contrast, the percentage of time was calculated by taking a
summary of each patient as the unit of analysis. These two
ways of performing calculations do not necessarily yield the
same results, because of within-patient correlations in meas-
urements. It seems prudent to provide both results.
The strong relation between hyperglycaemia and mortality and
morbidity is well known from the literature. Hence, hypergly-
caemia reduction forms the main goal of TGC. Surprisingly,
only nine studies explicitly defined a hyperglycaemic event and
employed different definitions of an event in terms of timing
and the BGL thresholds (between 150 to 250 mg/dl). Report-
ing the fraction of time above a threshold instead of the per-
centage of measurements above a threshold, without time
consideration, seems more useful as a proxy for reducing time
in a hyperglycaemic state. The hyperglycaemia index – calcu-
lated as the area between the curve and the hyperglycaemiaAvailable online http://ccforum.com/content/12/6/R139
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threshold divided by time – seems to be a useful time-
weighted indicator for hyperglycaemia. In some other studies,
the percentage of BGL measurements or time in a predefined
BGL range above the defined normoglycaemic threshold was
reported but without explicitly labeling them as
hyperglycaemia.
The quality of TGC in individual patients was rarely reported.
Useful indicators include the percentages of patients with well
and poorly controlled BGL, as defined by Carr and coworkers
[31]; patients with at least one BGL outside the blood glucose
target range; and patients who were not within the target
blood glucose range
On the whole, the authors of studies did not explain their
choices of specific subsets of indicators. It is conceivable that
an indicator was described by a specific statistic such as a
median because of an underlying non-normal distribution, in
order to permit sound statistical inference. Although this may
explain the specific choice of a statistic, it does not account for
the choice for the underlying concept in the first place.
Conclusion
When comparing the results of studies, one must consider dif-
ferences in case-mix, in insulin therapy, in other associated
therapies, in the power of the analysis and in outcome meas-
ures. The latter was the focus of this paper. The ambiguity and
variability in the definitions of indicators and the threshold val-
ues for reporting an event as hypoglycaemia or hyperglycae-
mia severely hamper comparability among studies. A main
problem is the absence of a 'gold standard' against which to
compare indicators. Although there are almost no studies
comparing different glycaemic metrics with relevant clinical
outcomes, such as severity-associated mortality, deciding
upon a common glycaemic vocabulary is an essential first
step.
One possible useful way to proceed is to investigate further
the relationship between indicators and clinical outcomes, for
example their prognostic value (for example [24,41]). A sec-
ond possible way is to ask a committee of experts to assess,
for a wide range of patients, the perceived adequacy of TGC.
Ideally, for this sample of patients the BGL would be continu-
ously measured, with insulin provision being based only on
protocol-based measurement sampling. Because this is an
ethically questionable approach (because not all measured
BGLs are acted upon), an alternative is to attempt to achieve
very high sampling of BGL measurements. Then, the indica-
tors could be assessed according to their concordance with
how well BGL is controlled, as assessed by expert opinion.
This approach is subjective but it can provide important insight
into the merits of indicators. In the meantime, studies should
report on a more comprehensive set of indicators, including at
least one pertaining to each of time, hyperglycaemia and
hypoglycaemia. One should also report results at the measure-
ment as well as patient level. An important message of this
review is that many indicators are not but should be precisely
defined, using formulas when necessary, to facilitate their
assessment and comparability.
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